• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer. J Clin 2005; 55: 74108.
  • 2
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer. J Clin 2006; 56: 10630.
  • 3
    Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett 2007; 249: 8796.
  • 4
    Moreaux J, Catala M. Carcinoma of the colon: long-term survival and prognosis after surgical treatment in a series of 798 patients. World J Surg 1987; 11: 8049.
  • 5
    Agrawal J, Syngal S. Colon cancer screening strategies. Curr Opin Gastroenterol 2005; 21: 5963.
  • 6
    Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC,Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54: e1179.
  • 7
    Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 1559.
  • 8
    Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 14727.
  • 9
    Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andren-Sandberg A, Lindholm L. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with. CEA, CA50 and. CA 19-9. Br J Cancer 1992; 65: 21521.
  • 10
    Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 134860.
  • 11
    Chen C, Chen LQ, Yang GL, Li Y. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases. Ai Zheng 2007; 26: 12216.
  • 12
    Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 2008; 55: 13842.
  • 13
    Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 6673.
  • 14
    Lindmark G, Bergstrom R, Pahlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 1995; 71: 10904.
  • 15
    Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994; 37: 2727.
  • 16
    Zhang JY, Wang X, Peng XX, Chan EK. Autoantibody responses in Chinese hepatocellular carcinoma. J Clin Immunol 2002; 22: 98105.
  • 17
    Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001; 108: 14115.
  • 18
    Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EK, Tan EM. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 2001; 125: 39.
  • 19
    Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53: 346871.
  • 20
    Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60: 177788.
  • 21
    Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future. Int J Biol Markers 2001; 16: 7386.
  • 22
    Lanzavecchia A, Lezzi G, Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 1999; 96: 14.
  • 23
    Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 1046.
  • 24
    Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 1620.
  • 25
    Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. Immunity to oncogenic proteins. Immunol Rev 1995; 145: 3359.
  • 26
    Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 118103.
  • 27
    Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 26570.
  • 28
    Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998; 76: 6528.
  • 29
    Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999; 83: 45664.
  • 30
    Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007; 11: 23544.
  • 31
    Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12: 13643.
  • 32
    Chen YT. Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J 2000; 6: S20817.
  • 33
    Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother 2002; 51: 57482.
  • 34
    Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62: 40417.
  • 35
    Kenedy AA, Cohen KJ, Loveys DA, Kato GJ, Dang CV. Identification and characterization of the novel centrosome-associated protein CCCAP. Gene 2003; 303: 3546.
  • 36
    Rubin RL, Joslin FG, Tan EM. An improved ELISA for anti-native DNA by elimination of interference by anti-histone antibodies. J Immunol Methods 1983; 63: 35966.
  • 37
    Shebzukhov YV, Koroleva EP, Khlgatian SV, Belousov PV, Kuz'mina KE, Radko BV, Longpre F, Lagarkova MA, Kadachigova TS, Gurova OV, Meshcheryakov AA, Lichinitser MR, et al. Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int J Cancer 2005; 117: 8006.
  • 38
    Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001; 98: 98249.
  • 39
    Struss AK, Romeike BF, Munnia A, Nastainczyk W, Steudel WI, Konig J, Ohgaki H, Feiden W, Fischer U, Meese E. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 2001; 20: 410714.
  • 40
    Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 122435.
  • 41
    Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995; 72: 63741.
  • 42
    Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sorensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brunner N. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 15664.
  • 43
    Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995; 1: 7012.
  • 44
    Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 1998; 4: 214752.
  • 45
    Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 33637.
  • 46
    Thomas P, Toth CA, Saini KS, Jessup JM, Steele G,Jr. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990; 1032: 17789.
  • 47
    Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47: 62430.
  • 48
    Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 44851.